In an adult with mild‑to‑moderate plaque psoriasis or acne, how should a topical ointment that combines a retinoid and a vitamin D analogue be applied, what are its contraindications, and what alternative treatments are available?

Topical Vitamin D Analogue Plus Retinoid or Corticosteroid for Mild-to-Moderate Plaque Psoriasis

Direct Answer

For mild-to-moderate plaque psoriasis, apply the fixed-combination product calcipotriene 0.005% plus betamethasone dipropionate 0.064% once daily as first-line therapy for up to 52 weeks; this combination is superior to either agent alone and achieves clear or almost-clear skin in 69-74% of patients. 1, 2, 3

---

Application Protocol

Standard Body Plaques

• Apply the calcipotriene-betamethasone combination ointment once daily to affected plaques; ointment formulations penetrate thick palmar and plantar plaques better than creams or foams. 2
• Do not exceed 100 g per week of any vitamin D analogue-containing product to prevent hypercalcemia and hypercalciuria. 2
• Continue treatment for up to 52 weeks; clinical improvement typically becomes evident at 8 weeks. 1, 2, 3

Scalp Psoriasis

• Use calcipotriene foam or calcipotriene plus betamethasone dipropionate gel (not ointment) for 4-12 weeks on the scalp. 1, 3

Facial and Intertriginous Psoriasis

• Apply calcipotriene combined with hydrocortisone (a lower-potency corticosteroid) for 8 weeks to minimize atrophy risk in thin-skinned areas. 1, 3

Palmar/Plantar Psoriasis

• Use calcipotriene ointment twice daily as first-line therapy; the ointment base provides superior penetration into thick palmar plaques. 2
• Add a topical corticosteroid for enhanced efficacy: apply the fixed-combination product once daily, or use a steroid-sparing regimen with twice-daily application initially, then switch to weekend-only corticosteroid while continuing calcipotriene five days per week. 2

---

Alternative Regimens When Fixed-Combination Is Unavailable

Sequential Induction-Maintenance Strategy

• Apply a high-potency corticosteroid (class 2-3) twice daily for weeks 1-4 as induction, then transition to calcipotriene twice daily for maintenance through week 52. 3
• For thick, chronic plaques, use ultrahigh-potency class 1 agents (clobetasol propionate or halobetasol propionate) for the initial 2-4 weeks, achieving 58-92% clearance rates. 3

Split-Regimen Strategies

• Weekday/weekend split: Apply vitamin D analogue twice daily Monday through Friday and high-potency corticosteroid twice daily Saturday and Sunday for maintenance. 1, 2, 3
• Morning/evening split: Apply high-potency corticosteroid in the morning and vitamin D analogue in the evening to maximize synergistic benefit while reducing adverse events. 1, 2, 3

---

Absolute Contraindications and Critical Pitfalls

Drug Interactions

• Never combine calcipotriene with salicylic acid; the acidic pH inactivates calcipotriene and eliminates its effectiveness. 1, 2, 3
• Apply vitamin D analogues after phototherapy sessions, not before; pre-treatment application blocks UVB transmission and increases minimal erythema dose. 1, 2
• Avoid UVA exposure immediately after application, as UVA radiation decreases the skin concentration of calcipotriene. 1, 2

Safety Limits

• Do not exceed 100 g per week total of vitamin D analogue products to prevent systemic hypercalcemia. 2
• Do not use class 1 ultrahigh-potency corticosteroids continuously beyond 2-4 weeks due to risk of HPA axis suppression, skin atrophy, striae, and telangiectasia. 3

---

Alternative Topical Treatments

When Vitamin D Analogues Are Not Tolerated

• Calcitriol ointment is less irritating than calcipotriene and may be preferred for highly sensitive skin, though palms generally tolerate calcipotriene well. 2
• Maxacalcitol can be considered for palmoplantar psoriasis when available (not marketed in the United States). 1, 2

Adding a Retinoid for Inadequate Response

• Tazarotene 0.1% cream applied once daily for 8-12 weeks achieves 40-51% treatment success in patients with inadequate response to optimized topical therapy. 1, 3
• Combine tazarotene with a medium- or high-potency corticosteroid to enhance efficacy while lowering the incidence of local irritation. 3
• Tazarotene 0.1% gel has comparable efficacy to fluocinonide cream for plaque psoriasis. 1

Adjunctive Therapy

• Apply non-medicated moisturizers 1-3 times daily to reduce itching, scaling, and desquamation; moisturizers are recommended as a routine component of therapy for all psoriasis patients. 3

---

Mechanism and Rationale for Combination Therapy

Vitamin D analogues bind nuclear vitamin D receptors, inhibiting keratinocyte proliferation and promoting differentiation, while corticosteroids act primarily as immunosuppressors targeting pro-inflammatory cytokines; this produces synergistic anti-psoriatic effects. 2, 4, 5

Vitamin D may restore epidermal barrier function impaired by corticosteroid use and counteract steroid-induced skin atrophy, while corticosteroids reduce perilesional irritation induced by vitamin D analogues. 4, 6

The combination has been shown to have a greater effect on the immune-mediated mechanisms of psoriasis than either monotherapy alone, with no serious adverse events—including skin striae or HPA axis suppression—observed during 52-week treatment periods. 3, 4

---

Monitoring and Management of Treatment Failure

If a patient appears to be failing therapy, first assess adherence rather than assume tachyphylaxis; true receptor down-regulation is rare. 2

Lack of response at 4 weeks should be communicated to patients to encourage adherence, as clinical improvement typically becomes evident at 8 weeks. 2